EDAP TMS announced the appointment of Glen French to its Board of Directors. Mr. French brings over 25 years of experience in the development and commercialization of diagnostic and therapeutic medical products.
Mr. French has a notable background, having co-founded, built, and sold three medical device companies, and taking a fourth company, Pulmonx Corporation, public. During his tenure at Pulmonx, the company achieved over 20% compound annual revenue growth and executed a $218.5 million initial public offering.
His extensive business and clinical expertise in innovative medical devices and technology is expected to guide EDAP's strategic decision-making. This appointment supports the company's efforts to expand the Focal One platform across multiple therapeutic areas, including endometriosis, benign prostatic hyperplasia, and pancreatic cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.